For a cardiologist trying to diagnose an intermittent arrhythmia, the standard of care is often a bulky, multi-wire Holter monitor that patients wear for 24 to 48 hours. It’s a clinical workhorse, but it’s also a relic. Now, a Palo Alto startup is betting that a single, stretchable patch can deliver a more complete picture, with the regulatory clearance to be used as a true diagnostic tool.
WearLinq, founded in 2019, has developed the eWave, a wireless, clinical-grade 6-lead ECG wearable that received FDA clearance for cardiac monitoring [LinkedIn]. The company pairs the hardware with a full diagnostic service, operating as an Independent Diagnostic Testing Facility (IDTF) to provide clinicians with expedited reports. It’s a bet that moving from one or two leads to six, while maintaining a patient-friendly form factor, can improve detection rates and reduce the need for repeat testing. The company has raised a total of $26.3 million (estimated) to scale its vision, including a $14 million Series A round led by AIX Ventures in late 2025 [HLTH, Dec 2025][Tracxn].
The clinical-grade wedge
WearLinq’s core differentiation is a hardware specification: a 6-lead, FDA-cleared patch. Most consumer wearables, like smartwatches, offer single-lead ECGs useful for spot checks but not for comprehensive clinical diagnosis. Traditional multi-lead Holter monitors require multiple electrodes and wires. WearLinq’s eWave device aims to sit in the middle, offering what it calls “multidimensional views of the heart” from a single, small wearable that can run for five days on a charge [wearlinq.com, 2026][finsmes.com, 2025]. For clinicians, the promise is a higher-fidelity, continuous data stream transmitted in near-real-time to a cloud platform, where AI-augmented analysis flags potential arrhythmias like atrial fibrillation [startup-seeker.com].
An integrated service, not just a device
The company’s strategy extends beyond selling hardware. By registering as an IDTF with clinical operations in Rockville, Maryland, WearLinq sells an end-to-end diagnostic service [LinkedIn]. A physician orders a test, the patient wears the eWave patch, and data flows to WearLinq’s platform. The company’s analysts and algorithms then generate a clinical report, which is returned to the ordering physician, typically in under 48 hours [finsmes.com, 2025]. This integrated model,device, software, and reporting service,is designed to slot directly into existing clinical workflows and reimbursement pathways, positioning WearLinq as a B2B healthcare solution rather than a direct-to-consumer wellness product.
Funding a commercial ramp
WearLinq’s funding history shows a significant capital infusion aimed at commercialization. Following earlier seed and venture rounds, the $14 million Series A in December 2025, led by AIX Ventures, was joined by $5 million in venture debt [HLTH, Dec 2025]. This capital pool of $26.3 million (estimated) has been supported by a diverse syndicate of over 15 investors, including SpringTide, Berkeley Catalyst Fund, and Alumni Ventures [Tracxn]. The funds are likely earmarked for scaling clinical deployments, further AI development, and the expansion hinted at by CEO Konrad Morzkowski into areas beyond cardiac monitoring [massdevice.com, 2026].
Seed (2024) | 0.7 | M USD
Venture Round (May 2025) | 11.6 | M USD
Series A (Dec 2025) | 14 | M USD
Venture Debt (Dec 2025) | 5 | M USD
The competitive rhythm
WearLinq does not have the field to itself. The market for remote cardiac monitoring includes established medical device giants and a cohort of newer digital health entrants. The company’s integrated service model and 6-lead form factor are its primary points of differentiation. However, commercial success will depend on convincing health systems and cardiology practices to adopt a new tool and change established referral patterns for Holter monitoring. The company’s 2024 acquisition of AMI Cardiac Monitoring, a move that brought on founder Dorothy Glodek, RN, may have provided crucial clinical operations expertise to navigate this adoption [wearlinq.com, 2026].
The path forward contains several key milestones to watch. The most immediate is the commercial rollout of the eWave device and the scaling of its IDTF service. Furthermore, the company has signaled an “exciting pipeline of AI products” and plans to expand its reach beyond cardiac monitoring [massdevice.com, 2026]. Realizing that broader vision will require additional clinical validations and possibly further regulatory clearances.
For patients with symptoms like palpitations, dizziness, or unexplained fatigue, the standard diagnostic journey often begins with that cumbersome Holter monitor. It’s a tried-and-true method, but its inconvenience can lead to poor patient compliance and missed arrhythmias. WearLinq is betting that a more comfortable, higher-fidelity wearable can lead to better adherence and, ultimately, more accurate diagnoses for this population. The next twelve months will test whether clinicians are ready to make the switch.
Sources
- [LinkedIn] WearLinq Company Profile | https://www.linkedin.com/company/wearlinq
- [HLTH, Dec 2025] WearLinq raises $14M to scale its wireless clinical-grade heart monitor | https://hlth.com/insights/news/wearlinq-raises-14m-to-scale-its-wireless-clinical-grade-heart-monito-2025-12-18
- [Tracxn] WearLinq Funding Rounds & Investors | https://tracxn.com/d/companies/wearlinq/__xF0-KEJvH89i_M3aHlS_s_Nu2x_n1_m6RbKkTuDowG8/funding-and-investors
- [wearlinq.com, 2026] WearLinq eWave Device Specifications | https://wearlinq.com
- [finsmes.com, 2025] WearLinq Launches eWave ECG Wearable | https://finsmes.com
- [startup-seeker.com] WearLinq AI-Augmented Analysis | https://startup-seeker.com/company/wearlinq~com
- [massdevice.com, 2026] WearLinq to expand access to FDA-cleared wearable ECG | https://www.massdevice.com/wearlinq-expand-access-wearable-ecg/
- [Crunchbase] WearLinq Acquisition of AMI Cardiac Monitoring | https://www.crunchbase.com/acquisition/wearlinq-acquires-ami-cardiac-monitoring--395d7004